welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Inhibiting NF-κB improves heart function in a mouse model of Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a devastating genetic disease that impairs cardiac and skeletal muscle development. People with DMD gradually lose ambulation in childhood, acquire respiratory and heart failure in young adulthood and succumb to the disease by their mid-thirties. Until recently, there has been no effective treatment for the characteristic muscle-wasting progression of this disease. Provisional FDA approval of the first DMD therapy (eteplirsen) and improved disease management strategies have extended the life span of DMD patients and expanded the field of DMD research into later-stage outcomes such as cardiomyopathy (heart failure).
rareRelated
-
The Gene-Edited Babies And CRISPR-Cas9 Controversy, ExplainedOutrage continues to grow over the news ...
-
Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilo...Wave Life Sciences Ltd., a biotechnology...
-
New lab technology could reveal treatments for muscle-wasting diseaseResearchers from Queen Mary University o...
-
Duchenne Muscular Dystrophy Research Fund (DMDfund)Duchenne Muscular Dystrophy Research Fun...
-
Jennifer Wallace Valdes, PTJennifer Wallace is the Program Director...
-
Tiffany CookTiffany Cook joined CureDuchenne in June...
-
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrop...Catabasis Pharmaceuticals, Inc., a clini...